alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,351–1,375 of 1,618 studies (page 55 of 65) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 1,618 studies tagged apolipoprotein — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Metallothionein-I and -III expression in animal models of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroscience 2006-10-04

Previous studies have described altered expression of metallothioneins (MTs) in neurodegenerative diseases like multiple sclerosis (MS), Down syndrome, and Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Glial fibrillary acidic protein and beta A4 protein deposits in temporal lobe of aging brain and senile dementia of the Alzheimer type: relation with the cognitive state and with quantitative studies of senile plaques and neurofibrillary tangles

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of neuroscience research 1990-12-01

The aim of this study was to compare brain glial fibrillary acidic protein (GFAP) levels to the modifications of cognitive functions (Blessed test score [BTS]), the density of the main neuropathological lesions (senile plaques [SP] and neurofibrillary tangles [NFT]), and the density of the two main subtypes of beta A4 deposits (classic plaques and diffuse deposits) in a series of patients with normal aging and senile dementia of the Alzheimer type of various degrees of severity. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American journal of medical genetics 2000-12-01

The apolipoprotein E genotype (APOE) is an established risk factor for Alzheimer disease, with the age-at-onset occurring earlier in individuals having at least one APOE epsilon 4 allele, relative to the APOE epsilon 3 or APOE epsilon 2 isoforms. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Dementia (Basel, Switzerland) 1994-09-01

The frequency of the epsilon 4 allele of the apolipoprotein E (apoE) is increased in familial and sporadic late-onset Alzheimer's disease, but its prevalence in non-Alzheimer dementias in Caucasian populations is unknown. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Rejuvenation research 2010-04-01

Alzheimer disease (AD) is a heterogeneous and progressive neurodegenerative disease, which in Western society mainly accounts for senile dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroradiology 2012-07-25

The objective of this study was to evaluate the effect of apolipoprotein E (APOE) epsilon 4 allele on regional cerebral perfusion (rCBF) changes using arterial spin labeling (ASL) magnetic resonance imaging (MRI) in subjects who are carriers or noncarriers of this risk factor for Alzheimer disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1989-01-01

We identified by a monoclonal antibody-based immunoradiometric assay high concentrations of an exocrine pancreatic protein called pancreatic thread protein (PTP) in several areas of Alzheimer disease (AD) brain. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American journal of human genetics 1992-11-01

A large number of familial Alzheimer disease (FAD) kindreds were examined to determine whether mutations in the amyloid precursor protein (APP) gene could be responsible for the disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A novel pathway for amyloid precursor protein processing

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurobiology of aging 2009-07-14

Amyloid precursor protein (APP) can be proteolytically processed along two pathways, the amyloidogenic that leads to the formation of the 40-42 amino acid long Alzheimer-associated amyloid β (Aβ) peptide and the non-amyloidogenic in which APP is cut in the middle of the Aβ domain thus precluding Aβ formation. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of neurochemistry 1993-12-01

The senile plaques found within the cerebral cortex and hippocampus of the Alzheimer disease brain contain beta-amyloid peptide (A beta) fibrils that are associated with a variety of macromolecular species, including dermatan sulfate proteoglycan and heparan sulfate proteoglycan. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of biotechnology 2006-09-27

Affibody (Affibody) ligands specific for human amyloid beta (Abeta) peptides (40 or 42 amino acid residues in size), involved in the progress of Alzheimer's disease, were selected by phage display technology from a combinatorial protein library based on the 58-amino acid residue staphylococcal protein A-derived Z domain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Current protein & peptide science 2004-02-01

The binding of amyloid beta peptides (Abeta) to plasma membranes appears to be a promising point of intervention in the events leading to the development of Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease reports 2017-09-28

Diverse pathogens are detected in Alzheimer's disease (AD) brains. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity

✓ Peer-reviewed alzhub usefulness score 38 out of 100. International journal of molecular sciences 2025-04-24

Clinical data, animal and cell studies show that some antidiabetic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), exert therapeutic effects in Alzheimer's disease (AD) via modulation of amyloid-β peptide (Aβ) metabolism. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American Journal of Neuroradiology 2025-11-19

In 4 of 5 patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. Greater regional Aβ PET signal reduction in areas involved by ARIA-E may reflect enhanced local Aβ clearance, reduced tracer binding site availability, impaired glymphatic flow from immune complex deposition, or other mechanisms. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hormone replacement therapy in women and vascular risk factors modify the association of a multi‐ancestry polygenic risk score with Alzheimer disease and related traits

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

The AD PRS was associated with AD in the ADSP sample, with odds ratios per standard deviation ranging from 1.14 to 1.52 across ancestry groups and robust validation in independent cohorts (Figure 1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Novel early‐onset Alzheimer‐associated genes influence risk through dysregulation of glutamate, immune activation, and intracell signaling pathways

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Alzheimer Disease (AD) is a highly polygenic dementia that presents with relatively earlier onset (≤65yo; EOAD) in about 5% of cases. 2 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-03-21

BackgroundTo date, cholinomimetics remain central in the pharmacotherapy of Alzheimer's disease (AD) dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropsychology 2025-03-01

The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genetic association of ABCA7 and PSEN1 polymorphisms with Alzheimer’s disease in the northeast Algerian population: Exploring risk factors

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Archives of Biological Sciences 2025-01-01

Alzheimer?s disease (AD) is a neurodegenerative disorder with a strong genetic component. 4 key findings →

Design: case-control study Participants: 98 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Astrocytes and Microglia in Alzheimer's Disease: Friends, Foes, or Both?

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Developmental Neurobiology 2025-10-31

Alzheimer's disease (AD), the most prevalent form of dementia, is neuropathologically defined by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 1,616 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed